Developing hybrid nanoparticles to deliver genetic medicines to target cells
Delivering therapeutic cargo to the right tissue without systemic side effects remains difficult. Manufacturing exosomes and engineered delivery vehicles at scale is expensive and technically complex, creating barriers to wider use of advanced therapies.
Exosiris is developing hybrid nanoparticles that combine cell-derived vesicles with lipid carriers to deliver genetic medicines to target cells. Its platform is designed for delivery inside the body, with applications in cancer immunotherapy and regenerative medicine.
What stands out about Exosiris
Co-founder Julien Caumartin served as CSO and Vice President Scientific Discovery at cancer immunotherapy biotech Invectys.
Source ↗Joined WILCO One with zero-interest loan support, repayable over five years without a personal guarantee.
Source ↗Selected for Bordeaux Care Lab's third cohort in 2026, operated by Unitec, CHU de Bordeaux and ALLIS-NA.
Source ↗Co-founder Maria Loustau holds a PhD in Biotechnology and has developed antibodies, nanobodies and CAR-T cell therapies.
Source ↗Reported in vitro feasibility and efficacy of its hybrid exosome–lipid nanoparticle platform for nucleic-acid delivery in the 2026 i-Lab project dossier.
Source ↗Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.